a2m
  • a2m
  • Services
    • Strategy
    • Market Access and Reimbursement
    • Health Economic Modelling
    • Pricing and Valuation
    • Biotechnology
    • Nutrition
  • Capabilities
  • Latest News
  • About
  • Publications
  • Achievements
  • Contact
  • Home
  • Latest News

Latest News

Innovation Premium for Innovative Orphan Drugs in Oncology and Rare Diseases

3 December 2020
Mark Nuijten

Lees meer

Guest lecture for Colombian American Chamber of Commerce on Pricing Policy for Orphan Drugs

25 November 2020
Mark Nuijten

Lees meer

Milestone of more than 10’000 views on our policy paper challenging the ICER

12 September 2020
Mark Nuijten

Lees meer

International Market Access Update

1 January 2019
Mark Nuijten

Lees meer

Economic impact of macrosomia

10 August 2018
Mark Nuijten

Lees meer

Increasing interest in our Pricing Model and Algorithm for "expensive" drugs

1 April 2018
Mark Nuijten

Lees meer

The true prices of drugs

1 December 2016
Mark Nuijten

Lees meer

A2M - Minerva in Vienna at ISPOR

2 November 2016
Mark Nuijten

Lees meer

Presentation of NICE model at European Hematology Association

1 November 2016
Mark Nuijten

Lees meer

ISPOR Vienna

2 October 2016
Mark Nuijten

Lees meer

  • «
  • 1
  • 2
  • »
Auteurs
  • Mark Nuijten
Latest News Blog
  • 3
    Dec
    Innovation Premium for Innovative Orphan Drugs in Oncology and Rare Diseases
  • 25
    Nov
    Guest lecture for Colombian American Chamber of Commerce on Pricing Policy for Orphan Drugs
  • 12
    Sep
    Milestone of more than 10’000 views on our policy paper challenging the ICER
Copyright by a2m, Mark Nuijten, 2018. All rights reserved.